TCT 243: Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Employee - CPC Clinical Research
• Grant Support/Research Contract - Bayer AG; Janssen Pharmaceuticals